Premium
Differential expression of natural killer cell activating receptors in blood versus bone marrow in patients with monoclonal gammopathy
Author(s) -
Costello Régis T.,
Boehrer Anne,
Sanchez Carole,
Mercier Delphine,
Baier Céline,
Treut Thérèse,
Sébahoun Gérard
Publication year - 2013
Publication title -
immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.297
H-Index - 133
eISSN - 1365-2567
pISSN - 0019-2805
DOI - 10.1111/imm.12082
Subject(s) - nkg2d , bone marrow , plasma cell leukemia , immune system , multiple myeloma , receptor , immunology , natural killer cell , innate immune system , biology , immunity , monoclonal , cancer research , monoclonal antibody , cytotoxicity , antibody , biochemistry , in vitro
Summary In monoclonal gammopathies (MG) and multiple myeloma (MM), normal natural cytotoxicity receptors (NCR) expression (NCR1/NKp46, NCR2/NKp44, NCR3/NKp30) is observed in natural killer (NK) cells. Nonetheless, except in plasma cell leukemia, few tumor plasmocytes are present in PB, while NK studies have been performed on peripheral blood (PB). For this reason we focused our attention on NK from bone marrow (BM). Our study demonstrates that the down‐regulation of NCR3/NKp30 is only detectable in NK from BM but not in PB, and shows a drastic decrease of both NKG2D and CD244/2B4/p38 expression in NK from BM in comparison with PB. In conclusion, our data more precisely describe the mechanism of immune escape of MG/MM from innate immunity since we show a drastic down regulation of 3 major activating NK receptors (NCR3/NKp30, NKG2D and CD244/2B4/p38) at the site of tumor, i.e BM, that was undetectable in PB. Further studies regarding immune regulatory drugs in MG/MM will imperiously require the assessment of immune cell status not only in PB but also in BM to obtain more relevant data regarding anti‐tumor efficacy.